Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Cardiovascular Clinical Trials Market

Cardiovascular Clinical Trials Market Size

Report ID: GMI7404
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

Cardiovascular Clinical Trials Market Size

Cardiovascular Clinical Trials Market was around USD 5.1 billion in 2022 and is projected to grow at a CAGR of over 6.1% up to 2032, due to the rising incidence of cardiovascular diseases such as heart failure, stroke, and coronary artery diseases.

To get key market trends

Download Free Sample

What are the growth opportunities in this market?

Download Free Sample

For instance, according to the World Heart Federation, cardiovascular diseases ranked among the top causes of global mortality, causing approximately 20.5 million deaths in 2021. Similarly, as per the World Health Organization reports, around 15 million individuals are suffering from strokes in as of June 2023, with 5 million fatalities and 5 million experiencing permanent disabilities. Thus, significant rise in prevalence of cardiovascular diseases upsurged the demand for enhanced cardiovascular therapies, thereby propelling the need for drug trials targeting cardiovascular diseases.

Cardiovascular Clinical Trials Market Report Attributes
Report Attribute	Details
Base Year:	2022
Cardiovascular Clinical Trials Market Size in 2022:	USD 5.1 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	6.1%
2032 Value Projection:	USD 9.2 Billion
Historical Data for:	2018 to 2022
No. of Pages:	180
Tables, Charts & Figures:	276
Segments covered:	Phase, Study design, Indication, End-use, & Region
Growth Drivers:	Rising burden of cardiovascular diseases globally Increasing number of contract research organizations (CROs) Increasing R&D expenditure towards clinical trials
Pitfalls & Challenges:	Patient recruitment and retention challenges

Learn more about the key segments shaping this market

Download Free Sample

Cardiovascular clinical trials refer to systematic and controlled research studies conducted to evaluate the safety, efficacy, and potential benefits of new medications, interventions, or medical devices related to cardiovascular health. These trials aim to advance medical knowledge and improve patient outcomes by investigating the prevention, diagnosis, and treatment of cardiovascular diseases such as heart failure, coronary artery diseases, and stroke. Researchers conduct these trials in phases, starting with smaller groups to assess safety and gradually progressing to larger populations to gather more comprehensive data on effectiveness and potential side effects.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cardiovascular clinical trials industry size was USD 5.1 billion in 2022 and is expected to reach USD 9.2 billion by 2032 due to the rising incidence of cardiovascular diseases, such as heart failure, stroke, and coronary artery diseases worldwide.

The phase III segment held 34.9% share of the cardiovascular clinical trials industry in 2022 and is expected to register appreciable CAGR from 2023-2032 on account of their pivotal role in evaluating treatment efficacy and safety before seeking regulatory approval.

North America cardiovascular clinical trials industry is expected to register 5.6% CAGR from 2023-2032 due to the presence of well-established CROs with expertise in cardiovascular clinical trials, including Worldwide Clinical Trials, ICON plc, Caidya, and several others in the region.

Eli Lilly & Company, IQVIA Inc, Worldwide Clinical Trials, ICON plc, Thermo Fisher Scientific (PPD Inc), Syneos Health, Medpace, Inc., Veeda Clinical Research, and WuXi AppTech are some of the major cardiovascular clinical trials companies worldwide.